Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients
March 20, 2018 07:46 ET
|
Exosome Diagnostics
Waltham, MA, March 20, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, recently published a study on the detection of the...
Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor
March 14, 2018 07:30 ET
|
Exosome Diagnostics
Boston, MA, March 14, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a market leader in liquid biopsy and the world’s first exosome-based diagnostics company announces a collaboration...
Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
January 16, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) announced today that it has added seven new patent applications to its existing Exclusive License Agreements with...
Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology
January 09, 2018 07:46 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has placed an Early Access version of its commercial Shahky system, which quantitively measures exosomal proteins, at...
Exosome Diagnostics Places Its First Early Access Shahky System within a Top 15 Pharmaceutical Laboratory
January 08, 2018 07:56 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics has announced the placement of the world’s first system for exosome specific protein analysis, the Shahky system, within a large...
Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network
December 04, 2017 07:33 ET
|
Exosome Diagnostics
Boston, MA, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that it has executed an agreement for coverage of its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test
November 27, 2017 08:16 ET
|
Exosome Diagnostics
Boston, MA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the national Medicare price for its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore),...
Exosome Diagnostics to Present a Novel Atlas of Exosomal mRNA and Long non-coding RNA Across Biofluids at American Society of Exosomes and Microvesicles Annual Meeting
October 11, 2017 07:30 ET
|
Exosome Diagnostics
Waltham, MA, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. will be presenting the company’s cutting edge long-RNAseq platform at this year’s American Society of Exosomes and...
CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic Tests
August 24, 2017 08:59 ET
|
Exosome Diagnostics | CareFirst
August 24, 2017 - Baltimore, Md. and Boston, Ma., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Exosome Diagnostics, Inc. (ExoDx) announced today that they have...
Exosome Diagnostics Launches the MedOncAlyzer™ Pan-Cancer Panel
August 09, 2017 09:02 ET
|
Exosome Diagnostics
Waltham, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, a leader in the liquid biopsy market, today announced the launch of the MedOncAlyzer 170, the first liquid biopsy pan-cancer...